Tech Company Financing Transactions
Viracta Therapeutics Funding Round
Forward Ventures, Latterell Venture Partners and NantKwest participated in a $18.4 million Series B funding round for Viracta Therapeutics. The funding round was recorded on 4/6/2017.
Transaction Overview
Company Name
Announced On
4/6/2017
Transaction Type
Venture Equity
Amount
$18,400,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2533 S. Coast Hwy. 101 210
Cardiff, CA 92007
USA
Cardiff, CA 92007
USA
Phone
Website
Email Address
Overview
Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Douglas Faller
Chief Executive Officer
Ivor Royston
Chief Medical Officer
Marshelle Warren
VP - Bus. Development
David Slack
VP - R & D
Robert McRae
Browse more venture capital transactions:
Prev: 4/6/2017: Datameer venture capital transaction
Next: 4/6/2017: ENOVIX venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs